1Yamada K, Furusawa S, Saito K, et al. Concurrent use of granulocyte colony-stimulating factor with low-dose cytosine arabinoside and aclarubicin for previously treated acute myelogenous leukemia : a pilot study. Leukeima, 1995, 9:10-14.
2Saito K, Furusawa S, Yamada K, et al. Comparison of low-dose cytosine arabinoside and aclarubicin in combination with granulocyte colony-stimulating factor to intermediate-dose cytosine arabinoside and mitoxantrone with or without etoposide in the treatment of relapsed acute myeloid leukemia. Rinsho Ketsueki, 1995, 36: 165-174.
5Yamada K,Furusawa S,Saito K,et al.Concurrent use of granulocyte colony stimulation factor with low dose cytosine arabinoside and aclarubicin for previously treated acute myelogenous leukemia:a pilot study.Leukemia,1995,9:10-14.
6Saito K, Nakamura Y, Aoyagi M, et al, Low dose cytarahine and aclarubrcin in combination with granulocyte colony stimulating factor ( CAG regimen) for previously treated patients with repiased or primary resistant acute myelogenous leukemia(AML) and refractory anemia with excess blast in transformation [J]. Int J Hematol ,2000,71(3) : 238-244.
7Li JM.Shen Y,Wu DP, et al. Aclarubicin and low-dose cytosine arabinoside in combination with granulocyte colonystimulating-factor in treating acute myeloid leukemia patients with relapsed or refractory disease and myelodysplastic syndrome:a multicenter study of 112 Chinese patients [J]. Int J Hematol,2005,82(1) :48-54.
8Greenberg P, Cox C, LeBeau MM, et al. International scoring system for prognosis in myeiodysplastic syndromes[J]. Blood, 1997,89 (6) : 2079-2088.
9Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia[J]. Blood, 2006,108(2) :419-425.
10Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms [J]. Blood,2002,100(7) :2292-2302.
